Login
Home
Charts
Search
Watchlist
Products

Apollo Hospitals Enterprise Ltd

APOLLOHOSP·NSE
8,835.50-0.86%Tue, 22 Sept '26 15:57

Apollo Hospitals Enterprise Ltd

APOLLOHOSP
NSE
8,835.50
-0.86%
|Tue, 22 Sept '26 15:57
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
1,27,041Cr
Close
Close Price
8,835.50
Industry
Industry
Hospitals
PE
Price To Earnings
60.79
PS
Price To Sales
4.81
Revenue
Revenue
26,430Cr
Rev Gr TTM
Revenue Growth TTM
17.20%
PAT Gr TTM
PAT Growth TTM
33.20%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
4,8474,8514,9445,0865,5895,5275,5925,8426,3046,4776,6067,044
Growth YoY
Revenue Growth YoY%
14.013.814.915.115.313.913.114.912.817.218.120.6
Expenses
ExpensesCr
4,2194,2374,3034,4114,7744,7654,8234,9905,3625,5125,5955,951
Operating Profit
Operating ProfitCr
6286146416758167627708529419651,0111,092
OPM
OPM%
12.912.713.013.314.613.813.814.614.914.915.315.5
Other Income
Other IncomeCr
262937494469725461495462
Interest Expense
Interest ExpenseCr
111113119116118110115108110113119120
Depreciation
DepreciationCr
163167190177185185211215218219224235
PBT
PBTCr
379363368430557536516583675682722799
Tax
TaxCr
130109110115162157101142181166170188
PAT
PATCr
249254258316396379415441494516551610
Growth YoY
PAT Growth YoY%
16.956.677.582.059.049.160.439.824.836.133.038.4
NPM
NPM%
5.15.25.26.27.16.97.47.57.88.08.38.7
EPS
EPS
16.217.117.621.226.325.927.130.133.234.936.840.4
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
4,8474,8514,9445,0865,5895,5275,5925,8426,3046,4776,6067,044
Growth YoY
Revenue Growth YoY%
14.013.814.915.115.313.913.114.912.817.218.120.6
Expenses
ExpensesCr
4,2194,2374,3034,4114,7744,7654,8234,9905,3625,5125,5955,951
Operating Profit
Operating ProfitCr
6286146416758167627708529419651,0111,092
OPM
OPM%
12.912.713.013.314.613.813.814.614.914.915.315.5
Other Income
Other IncomeCr
262937494469725461495462
Interest Expense
Interest ExpenseCr
111113119116118110115108110113119120
Depreciation
DepreciationCr
163167190177185185211215218219224235
PBT
PBTCr
379363368430557536516583675682722799
Tax
TaxCr
130109110115162157101142181166170188
PAT
PATCr
249254258316396379415441494516551610
Growth YoY
PAT Growth YoY%
16.956.677.582.059.049.160.439.824.836.133.038.4
NPM
NPM%
5.15.25.26.27.16.97.47.57.88.08.38.7
EPS
EPS
16.217.117.621.226.325.927.130.133.234.936.840.4

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
6,2157,2568,2439,61711,24710,56014,66316,61319,05921,79425,22926,430
Growth
Revenue Growth%
20.016.813.616.716.9-6.138.913.314.714.315.817.2
Expenses
ExpensesCr
5,5276,5277,4508,5549,6609,42312,47814,56316,66918,77221,45922,420
Operating Profit
Operating ProfitCr
6887297931,0641,5871,1372,1852,0502,3913,0223,7694,010
OPM
OPM%
11.110.09.611.114.110.814.912.312.513.914.915.2
Other Income
Other IncomeCr
8865323222510637290126233217226
Interest Expense
Interest ExpenseCr
180257295327533449379381449459450462
Depreciation
DepreciationCr
264314359396620573601615687758876897
PBT
PBTCr
3322221713736602211,5781,1441,3812,0392,6612,877
Tax
TaxCr
979111217322585477256446534658705
PAT
PATCr
235131601994351361,1018889351,5052,0032,172
Growth
PAT Growth%
-27.7-44.3-54.6234.5118.3-68.7709.6-19.45.361.033.133.2
NPM
NPM%
3.81.80.72.13.91.37.55.34.96.97.98.2
EPS
EPS
17.015.98.417.032.710.773.457.062.5100.6135.0145.3
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
6,2157,2568,2439,61711,24710,56014,66316,61319,05921,79425,22926,430
Growth
Revenue Growth%
20.016.813.616.716.9-6.138.913.314.714.315.817.2
Expenses
ExpensesCr
5,5276,5277,4508,5549,6609,42312,47814,56316,66918,77221,45922,420
Operating Profit
Operating ProfitCr
6887297931,0641,5871,1372,1852,0502,3913,0223,7694,010
OPM
OPM%
11.110.09.611.114.110.814.912.312.513.914.915.2
Other Income
Other IncomeCr
8865323222510637290126233217226
Interest Expense
Interest ExpenseCr
180257295327533449379381449459450462
Depreciation
DepreciationCr
264314359396620573601615687758876897
PBT
PBTCr
3322221713736602211,5781,1441,3812,0392,6612,877
Tax
TaxCr
979111217322585477256446534658705
PAT
PATCr
235131601994351361,1018889351,5052,0032,172
Growth
PAT Growth%
-27.7-44.3-54.6234.5118.3-68.7709.6-19.45.361.033.133.2
NPM
NPM%
3.81.80.72.13.91.37.55.34.96.97.98.2
EPS
EPS
17.015.98.417.032.710.773.457.062.5100.6135.0145.3

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
7070707070727272727272
Reserves
ReservesCr
3,2613,2403,1823,2643,2704,5315,5516,1266,8648,1409,408
Current Liabilities
Current LiabilitiesCr
1,2509631,5671,9562,3372,0382,4343,3254,6654,5796,481
Non Current Liabilities
Non Current LiabilitiesCr
2,7013,7183,6623,7595,5314,5774,9324,5724,7687,4265,741
Total Liabilities
Total LiabilitiesCr
7,3608,1198,6139,18311,33811,41713,26914,42816,75320,65722,197
Current Assets
Current AssetsCr
1,9752,1292,2202,2822,6473,6414,0614,3375,2807,0296,900
Non Current Assets
Non Current AssetsCr
5,3855,9906,3936,9018,6927,7759,20910,09111,47313,62915,297
Total Assets
Total AssetsCr
7,3608,1198,6139,18311,33811,41713,26914,42816,75320,65722,197
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
7070707070727272727272
Reserves
ReservesCr
3,2613,2403,1823,2643,2704,5315,5516,1266,8648,1409,408
Current Liabilities
Current LiabilitiesCr
1,2509631,5671,9562,3372,0382,4343,3254,6654,5796,481
Non Current Liabilities
Non Current LiabilitiesCr
2,7013,7183,6623,7595,5314,5774,9324,5724,7687,4265,741
Total Liabilities
Total LiabilitiesCr
7,3608,1198,6139,18311,33811,41713,26914,42816,75320,65722,197
Current Assets
Current AssetsCr
1,9752,1292,2202,2822,6473,6414,0614,3375,2807,0296,900
Non Current Assets
Non Current AssetsCr
5,3855,9906,3936,9018,6927,7759,20910,09111,47313,62915,297
Total Assets
Total AssetsCr
7,3608,1198,6139,18311,33811,41713,26914,42816,75320,65722,197

Cash Flow

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
5976235379051,2931,2651,6961,3771,9202,1362,856
Investing Cash Flow
Investing Cash FlowCr
-888-1,152-405-711-289-863-847-871-1,537-3,383-2,148
Financing Cash Flow
Financing Cash FlowCr
330477-109-215-910-340-792-633-3111,319-478
Net Cash Flow
Net Cash FlowCr
39-5224-20956157-1277273230
Free Cash Flow
Free Cash FlowCr
-393-46-842337829841,044253785439925
CFO To PAT
CFO To PAT%
253.9474.8901.6454.4297.4929.9154.0155.1205.4141.9142.6
CFO To EBITDA
CFO To EBITDA%
86.885.567.785.181.5111.277.667.280.370.775.8
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
5976235379051,2931,2651,6961,3771,9202,1362,856
Investing Cash Flow
Investing Cash FlowCr
-888-1,152-405-711-289-863-847-871-1,537-3,383-2,148
Financing Cash Flow
Financing Cash FlowCr
330477-109-215-910-340-792-633-3111,319-478
Net Cash Flow
Net Cash FlowCr
39-5224-20956157-1277273230
Free Cash Flow
Free Cash FlowCr
-393-46-842337829841,044253785439925
CFO To PAT
CFO To PAT%
253.9474.8901.6454.4297.4929.9154.0155.1205.4141.9142.6
CFO To EBITDA
CFO To EBITDA%
86.885.567.785.181.5111.277.667.280.370.775.8

Ratios

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
18,42616,23114,78416,98615,83041,73964,93761,96391,33195,2191,06,8091,27,041
Price To Earnings
Price To Earnings
78.073.5125.972.034.8277.561.575.7101.765.955.060.8
Price To Sales
Price To Sales
3.02.21.81.81.44.04.43.74.84.44.24.8
Price To Book
Price To Book
5.54.94.65.14.89.111.610.013.211.611.313.4
EV To EBITDA
EV To EBITDA
30.125.722.318.911.839.731.232.040.033.730.333.9
Profitability Ratios
Profitability Ratios
GPM
GPM%
44.240.341.241.440.935.436.236.336.335.934.734.7
OPM
OPM%
11.110.09.611.114.110.814.912.312.513.914.915.2
NPM
NPM%
3.81.80.72.13.91.37.55.34.96.97.98.2
ROCE
ROCE%
8.67.67.110.317.87.720.214.514.915.517.317.3
ROE
ROE%
7.14.01.86.013.03.019.614.313.518.321.121.1
ROA
ROA%
3.21.60.72.23.81.28.36.25.67.39.09.0
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
18,42616,23114,78416,98615,83041,73964,93761,96391,33195,2191,06,8091,27,041
Price To Earnings
Price To Earnings
78.073.5125.972.034.8277.561.575.7101.765.955.060.8
Price To Sales
Price To Sales
3.02.21.81.81.44.04.43.74.84.44.24.8
Price To Book
Price To Book
5.54.94.65.14.89.111.610.013.211.611.313.4
EV To EBITDA
EV To EBITDA
30.125.722.318.911.839.731.232.040.033.730.333.9
Profitability Ratios
Profitability Ratios
GPM
GPM%
44.240.341.241.440.935.436.236.336.335.934.734.7
OPM
OPM%
11.110.09.611.114.110.814.912.312.513.914.915.2
NPM
NPM%
3.81.80.72.13.91.37.55.34.96.97.98.2
ROCE
ROCE%
8.67.67.110.317.87.720.214.514.915.517.317.3
ROE
ROE%
7.14.01.86.013.03.019.614.313.518.321.121.1
ROA
ROA%
3.21.60.72.23.81.28.36.25.67.39.09.0
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Apollo Hospitals is not just a hospital chain - it is India’s largest and most complete private healthcare ecosystem, built over four decades to touch a patient at every point of care, from a neighbourhood pharmacy to a robotic brain surgery. It began in 1983 when Dr. Prathap C Reddy opened India’s first corporate hospital in Chennai, defying the notion that world-class care was only for the wealthy, and that same year it opened its first pharmacy, planting the seeds of a model that would eventually span hospitals, clinics, diagnostics, pharmacies, and a digital health platform. The recurring approach is to build a clinical asset of the highest complexity, earn trust, and then extend that trust into simpler, higher-volume touchpoints - pharmacies, diagnostics, primary clinics, and a digital app - so that the patient stays inside the Apollo system for life. # Business segments Four engines at different stages - a mature hospital network that anchors the group, a pharmacy-distribution and digital platform being merged into a separate listed entity, a retail-health and diagnostics chain that feeds the hospitals, and a small but growing insurance and consumer-products layer - each built to capture a different part of the patient’s healthcare journey. ## 1. Healthcare Services: the high-acuity hospital network that earns the group’s reputation **Complex, life-saving procedures - cardiac, cancer, neuro, transplant - generate the clinical brand that makes every other part of the ecosystem credible.** - **Fee-for-service on high-intensity episodes** - the division earns revenue per inpatient stay, with an average of ₹187,208 per case in Q4 FY26, driven more by the complexity of the case mix than by simply filling more beds. - **“CONGO-T” specialties concentrate the skill** - Cardiac, Oncology, Neurosciences, Gastroenterology, Orthopedics, and Transplant together form the clinical core; in FY26, cardiology alone brought in 19% of in-patient revenue and oncology 16%, meaning nearly two of every five rupees came from heart and cancer care. - **Technology as a magnet for patients and surgeons** - the network houses South East Asia’s first proton therapy centre in Chennai, South Asia’s first ZAP-X radiosurgery platform for brain tumours, and India’s first AI-Precision Oncology Centre, all of which pull in complex cases that community hospitals cannot handle. - **Quality standards benchmarked to the world’s best** - the Apollo Standards of Clinical Care (TASCC) scorecard tracks 40 clinical parameters against institutions like the Cleveland Clinic and Mayo Clinic, while JCI accreditation at eight hospitals makes the quality promise externally verifiable. - **A physical footprint that is still expanding** - 78 hospitals with 10,970 capacity beds as of March 2026, with four new hospitals commissioned in FY26 alone and 3,415 more beds under development across 11 projects, including a greenfield hospital in Varanasi, a Build, Operate and Manage agreement in Mumbai, and a mix of greenfield, lease facility, and brownfield expansion in Bengaluru. ## 2. Apollo HealthCo: the pharmacy backbone and digital front door, soon to be a standalone listed company **A wholesale distribution engine that supplies 7,289 pharmacies and a digital platform with 47 million registered users - together forming an omni-channel health platform that is being merged with India’s largest pharma wholesaler and listed separately.** - **Exclusive supplier to a nationwide pharmacy chain** - the distribution business procures pharmaceuticals, FMCG, and private-label products and is the sole supplier to Apollo Pharmacies Limited under a long-term contract, giving it a procurement-cost advantage over local chemists and regional chains. - **Private label lifts margins** - roughly 15.3% of omni-channel pharmacy sales in Q4 FY26 came from Apollo’s own private-label and generic products, which carry better economics than selling third-party brands. - **The digital platform turns trust into daily transactions** - Apollo 24/7 handles approximately 15,000 doctor consultations and 51,600 medicine orders every day, with a customer-acquisition cost brought down to ₹250-400 per user by leaning on the Apollo brand and its 6,000-plus physical outlets rather than pure digital marketing spend. - **A Clinical Intelligence Engine that only Apollo could build** - the platform’s AI-powered decision-support tool understands over 1,200 diseases and 800 symptoms prevalent in South Asia, trained on Apollo’s own clinical knowledge base and peer-reviewed by more than 500 of its specialists, a data moat no pure-tech competitor can replicate. - **The Keimed merger creates a distribution giant** - a composite scheme of arrangement will demerge Apollo HealthCo, merge it with Keimed (which serves 70,000-plus pharmacies across 18 states with 96 distribution centres), and list the combined entity as Apollo Healthtech Limited, with AHEL shareholders owning 42.1% of the new company. ## 3. Apollo Health & Lifestyle: the out-of-hospital network that catches patients early and feeds the hospitals **A multi-brand chain of clinics, diagnostics labs, dialysis units, dental centres, and day-surgery facilities that operates on a hub-and-spoke model - treating everyday needs while identifying patients who need escalated hospital care.** - **Diagnostics as the high-volume entry point** - 2,501 centres including 114 labs and over 2,350 collection centres processed more than 8.6 million tests, with a central reference lab using AI to auto-validate 77% of results across 164 tests, speeding up turnaround in a business where speed wins customers. - **Each sub-brand targets a specific recurring need** - Apollo Sugar manages diabetes with connected glucometers and long-term care packages, Apollo Dialysis runs units often under public-private partnership models with state governments, and Apollo Spectra performs short-stay surgeries in orthopedics, urology, and bariatrics, all on a fee-for-service basis. - **A feeder system for the tertiary hospitals** - the hub-and-spoke design means a patient diagnosed at an Apollo Clinic or diagnostic centre can be referred directly into the main hospital network for complex treatment, keeping the patient within the Apollo ecosystem. - **The maternity and fertility business is being reshaped** - in May 2026, AHLL agreed to sell its Apollo Cradle and Apollo Fertility centres to Cloudnine for cash of ₹7,650 million plus a roughly 9.9% equity stake in the combined entity, creating one of India’s largest maternity and fertility platforms while AHLL retains a stake in the upside. ## 4. Insurance and consumer products: early-stage bets on the edges of the ecosystem **A corporate insurance agency and a newly acquired FMCG distribution arm extend the Apollo brand into health coverage and everyday wellness products, both still nascent.** - **Insurance sold without a field force** - Apollo 24|7 Insurance Services Limited, incorporated in September 2024, acts as a corporate agent for life, general, and health insurance, distributing policies through digital channels and a 300-seat call centre rather than an agent network, keeping distribution costs low. - **Consumer products ride the pharmacy shelf space** - Apollo Consumer Products Ltd, acquired in March 2026, will trade and distribute FMCG goods including food, personal care, and wellness products through the same physical retail and digital networks that already move pharmaceuticals, turning existing shelf space into a new revenue line. # Group structure and partners **A listed parent company with a web of subsidiaries that hold individual hospital assets, a soon-to-be-separated pharmacy and digital entity backed by Advent International, and a retail-health subsidiary that just became wholly owned - all governed by non-compete boundaries that keep each engine in its lane.** - **Hospitals are held in asset-specific subsidiaries** - individual hospitals in Kolkata, Lucknow, Bangalore, Ahmedabad, Guwahati, Indore, and other cities sit inside separate subsidiary companies, many with local minority partners, which isolates project-level risk and makes future stake sales or acquisitions cleaner. - **Advent International owns a slice of the pharmacy-digital business** - the private-equity firm invested ₹2,475 crore in Apollo HealthCo in September 2024 for approximately 16.9%, and will hold 12.1% of the post-merger Apollo Healthtech entity, aligning external capital with the listing catalyst. - **A non-compete framework keeps the engines from colliding** - under a Business Framework Agreement, AHEL cannot run an e-commerce or retail pharmacy business outside its hospital pharmacies, while Apollo HealthCo cannot deliver physical healthcare services; the Apollo 24/7 platform remains the exclusive digital front-end for the entire group.

Documents — Apollo Hospitals Enterprise Ltd

  • Q1 FY2027 Earnings Call Transcript (Jun 2026, PDF): https://www.stockscans.in/document/as-c993a90eac9a5fd4aa589405.pdf
  • Q3 FY2026 Earnings Call Transcript (Dec 2025, PDF): https://www.stockscans.in/document/13jgry46qoetueb84u1fdwy0.pdf
  • Q2 FY2026 Earnings Call Transcript (Sep 2025, PDF): https://www.stockscans.in/document/i6662nxp8ytountmmt0hxjvi.pdf
  • Q1 FY2026 Earnings Call Transcript (Jun 2025, PDF): https://www.stockscans.in/document/ehrj1zjj5shvl8w8p29ixuty.pdf
  • Q4 FY2025 Earnings Call Transcript (Mar 2025, PDF): https://www.stockscans.in/document/tgltl7l1m9809t1evfozd78k.pdf
  • Q3 FY2025 Earnings Call Transcript (Dec 2024, PDF): https://www.stockscans.in/document/ru8i2ktcd0sq3di4qzgs4o0h.pdf
  • Q2 FY2025 Earnings Call Transcript (Sep 2024, PDF): https://www.stockscans.in/document/oph3sm49h8fzx5hzw62kjavo.pdf
  • Q1 FY2025 Earnings Call Transcript (Jun 2024, PDF): https://www.stockscans.in/document/i22zu83l6jyocrk9ddwbbjzn.pdf
  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/o5nlpf5g9jasesfy5iapice0.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/gwv236401ga1i339pvdkts6u.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/qiy15cx6lobt276hmrplr0f0.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/fmawe6egfyrdbdocifuybs63.pdf
  • Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/ezckmeleuxy5xo4fh7jb633k.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/oryowg9r1963uwissm9u33w9.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/igc0ks2wdb7ftzszkvfhtu63.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/9gvm0n0aafmwbjzm18wuh0bm.pdf
  • Q1 FY2027 Investor Presentation (Jun 2026, PDF): https://www.stockscans.in/document/ljycktow89bo979p8f8q3f8z.pdf
  • Q4 FY2026 Investor Presentation (Mar 2026, PDF): https://www.stockscans.in/document/f4nyv7fbhj2sazh17gtc2lns.pdf
  • Q3 FY2026 Investor Presentation (Dec 2025, PDF): https://www.stockscans.in/document/vt6vfzwr7awyca8o0o34km40.pdf
  • Q2 FY2026 Investor Presentation (Sep 2025, PDF): https://www.stockscans.in/document/tjdp41y31pluz211eecaem23.pdf
  • Q1 FY2026 Investor Presentation (Jun 2025, PDF): https://www.stockscans.in/document/2cl3xu3dita1iva8moiufzw9.pdf
  • Q4 FY2025 Investor Presentation (Mar 2025, PDF): https://www.stockscans.in/document/iwtoko1tgn7kzbxry760xgos.pdf
  • Q3 FY2025 Investor Presentation (Dec 2024, PDF): https://www.stockscans.in/document/qqhh8fb0lp67dj8uo73n91rv.pdf
  • Q2 FY2025 Investor Presentation (Sep 2024, PDF): https://www.stockscans.in/document/oqx7ktswyns4wgj3ajzp2r3a.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/6qij2hz5hf20ijb6rcz6jm1o.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/cy1flswyc2czlii4201lbw0h.pdf
  • FY2023 Annual Report (PDF): https://www.stockscans.in/document/ag1lr39e7q2yi2hqd8e3p7q3.pdf
  • FY2022 Annual Report (PDF): https://www.stockscans.in/document/fpkb8ajii5ud28y6odqeg77w.pdf
  • FY2021 Annual Report (PDF): https://www.stockscans.in/document/fsz93rfe8xyoh53pmy5i7c35.pdf
  • FY2020 Annual Report (PDF): https://www.stockscans.in/document/8thq8evpnjsyngtx5fe1li5x.pdf

Concall Transcript Summaries — Apollo Hospitals Enterprise Ltd

  • Q1 FY2027 Concall Transcript Summary (Jun 2026): https://www.stockscans.in/company/NSE%3AAPOLLOHOSP/transcript-notes/202606/as-c993a90eac9a5fd4aa589405.pdf
  • Q3 FY2026 Concall Transcript Summary (Dec 2025): https://www.stockscans.in/company/NSE%3AAPOLLOHOSP/transcript-notes/202512/13jgry46qoetueb84u1fdwy0.pdf
  • Q2 FY2026 Concall Transcript Summary (Sep 2025): https://www.stockscans.in/company/NSE%3AAPOLLOHOSP/transcript-notes/202509/i6662nxp8ytountmmt0hxjvi.pdf
  • Q1 FY2026 Concall Transcript Summary (Jun 2025): https://www.stockscans.in/company/NSE%3AAPOLLOHOSP/transcript-notes/202506/ehrj1zjj5shvl8w8p29ixuty.pdf
  • Q4 FY2025 Concall Transcript Summary (Mar 2025): https://www.stockscans.in/company/NSE%3AAPOLLOHOSP/transcript-notes/202503/tgltl7l1m9809t1evfozd78k.pdf
  • Q3 FY2025 Concall Transcript Summary (Dec 2024): https://www.stockscans.in/company/NSE%3AAPOLLOHOSP/transcript-notes/202412/ru8i2ktcd0sq3di4qzgs4o0h.pdf
  • Q2 FY2025 Concall Transcript Summary (Sep 2024): https://www.stockscans.in/company/NSE%3AAPOLLOHOSP/transcript-notes/202409/oph3sm49h8fzx5hzw62kjavo.pdf
  • Q1 FY2025 Concall Transcript Summary (Jun 2024): https://www.stockscans.in/company/NSE%3AAPOLLOHOSP/transcript-notes/202406/i22zu83l6jyocrk9ddwbbjzn.pdf